The gut microbiota participates in the effect of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C): a multicenter, prospective, pre-post study

Abstract Background Interindividual variation characterizes the relief experienced by constipation-predominant irritable bowel syndrome (IBS-C) patients following linaclotide treatment. Complex bidirectional interactions occur between the gut microbiota and various clinical drugs. To date, no establ...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Jianyun Zhou, Haoqi Wei, An Zhou, Xu Xiao, Xia Xie, Bo Tang, Hui Lin, Li Tang, Ruiping Meng, Xiaoying Yuan, Jing Zhang, Cheng Huang, Baobao Huang, Xiping Liao, Tingting Zhong, Suyu He, Sai Gu, Shiming Yang
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMC 2024-01-01
Rangatū:	Journal of Translational Medicine
Ngā marau:	IBS-C Linaclotide Gut microbiome Blautia SCFAs
Urunga tuihono:	https://doi.org/10.1186/s12967-024-04898-1
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!